Moreover, it exerts antiproliferative effects in NET providing tumor control in many patients .[13–15] We therefore decided to initiate an add-on therapy with IFN taking into consideration that alternative therapy options such as Peptide receptor radionuclide therapy[16,17] or everolimus[16] were not considered eligible due to negative SSR expression in liver metastases or, in case of everolimus, the lack of anti-secretory effect and minimal cytoreductive ‘potential. The gene discussed is IFNA1; the disease is neoplasm.